Overview

Freedom Study: Myfortic in Kidney Transplant Patients

Status:
Completed
Trial end date:
2005-05-01
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to evaluate that 3 immunosuppressant regimens will have comparable kidney function results in kidney transplant patients.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Mycophenolate mofetil
Mycophenolic Acid